Submissions for variant NM_007294.4(BRCA1):c.2331_2332dup (p.Gly778fs)

dbSNP: rs431825390

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000238952	SCV000783617	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2017-12-15	reviewed by expert panel	curation	Variant allele predicted to encode a truncated non-functional protein.
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000238952	SCV000296389	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2015-09-25	criteria provided, single submitter	clinical testing
GeneDx	RCV000486921	SCV000564725	pathogenic	not provided	2016-05-06	criteria provided, single submitter	clinical testing	This duplication of two nucleotides is denoted BRCA1 c.2331_2332dupTG at the cDNA level and p.Gly778ValfsX15 (G778VfsX15) at the protein level. This variant is also known as BRCA1 2450_2451dupTG or 2451insTG using alternate nomenclature. The normal sequence, with the bases that are duplicated in braces, is ATTA[TG]GCAC. The duplication causes a frameshift, which changes a Glycine to a Valine at codon 778, and creates a premature stop codon at position 15 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. We consider this variant to be pathogenic.
Ambry Genetics	RCV000575312	SCV000665887	pathogenic	Hereditary cancer-predisposing syndrome	2016-11-28	criteria provided, single submitter	clinical testing	The c.2331_2332dupTG pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a duplication of TG at nucleotide position 2331, causing a translational frameshift with a predicted alternate stop codon. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae	RCV002518502	SCV003237310	pathogenic	Hereditary breast ovarian cancer syndrome	2022-09-18	criteria provided, single submitter	clinical testing	This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 252382). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. This sequence change creates a premature translational stop signal (p.Gly778Valfs*15) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584).
Baylor Genetics	RCV000238952	SCV004216836	likely pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2023-02-14	criteria provided, single submitter	clinical testing
Sharing Clinical Reports Project (SCRP)	RCV000238952	SCV000115101	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2011-10-17	no assertion criteria provided	clinical testing
GeneDx	RCV000159905	SCV000210021	pathogenic	Familial cancer of breast	2014-06-25	flagged submission	clinical testing	This insertion of 2 nucleotides is denoted BRCA1 c.2332_2333insTG (a.k.a c.2331_2332dupTG) at the cDNA level and p.Gly778ValfsX15 (G778VfsX15) at the protein level. The normal sequence, with the bases that are inserted in brackets, is TATG{insTG}GCAC. The insertion causes a frameshift, which changes a Glycine to a Valine at codon 778 in exon 10, and creates a premature stop codon at position 15 of the new reading frame. This mutation is also known as BRCA1 2451insTG using alternate nomenclature. Although this mutation has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. We consider this mutation to be pathogenic. and is indicative of Hereditary Breast and Ovarian Cancer (HBOC), an autosomal dominant condition that predisposes to early onset breast cancer, ovarian and fallopian tube cancer, as well as other cancers. Breast and ovarian cancer are the predominant BRCA1-related cancers that unaffected female mutation carriers are at risk to develop. The lifetime risk for breast cancer is estimated to be 57 to 84% and the lifetime risk for ovarian cancer is estimated to be 24 to 54% (Antoniou 2003, Chen 2007, Ford 1998). BRCA1 mutations have also been reported in women with fallopian tube carcinoma, primary peritoneal carcinoma, and uterine serous carcinoma (Levine 2003, Pennington 2013). Graeser et al. (2009) found that women who harbor a pathogenic BRCA1 mutation have an increased risk for contralateral breast cancer that is dependent on age at initial diagnosis. It is estimated that the risk to develop a second breast cancer within 10 years of the first diagnosis if initially diagnosed less than age 40 years of age is 31%, between the ages of 40 and 50 is 11% and after the age of 50 is 8%. Additionally, it is estimated that the risk to develop a second breast cancer within 25 years of their first diagnosis if initially diagnosed less than age 40 years of age is 63%, between the ages of 40 and 50 is 44% and after the age of 50 is 20%. Other cancer risks associated with a BRCA1 pathogenic variant include approximately a 20% risk for prostate cancer in male carriers (Thompson 2002), a 4% risk for male breast cancer (Liede 2004), and an estimated 1 to 3% risk for pancreatic cancer in both men and women (Brose 2002, Thompson 2002). The variant is found in BRCA panel(s).